CDX-1307, which has been evaluated for the treatment of advanced colorectal, pancreatic, bladder, ovarian and breast cancers
CDX-1307 could be big imo.
Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target dendritic cells and macrophages -- key cells within the immune system. To generate an effective immune response, a vaccine needs to be taken up and processed by these cells, which are also known as Antigen Presenting Cells or APCs. Our recombinant antibody vaccines are designed as off-the-shelf products that enhance the efficiency and effectiveness of vaccination by targeting the vaccine to APCs in the body. Our product candidates using the APC technology include CDX-1307, which has been evaluated for the treatment of advanced colorectal, pancreatic, bladder, ovarian and breast cancers in two Phase 1 trials. Additional new product candidates are planned to enter clinical development for oncology and infectious disease.
The body's immune system is tasked with recognizing and combating cancer cells, viruses, bacteria and other disease-causing organisms. This defense is carried out mainly by white blood cells and their specific subsets, T-cells, and B-cells, which mediate cell-mediated immune responses and antibody-based immune responses. Professional antigen presenting cells or APCs (including dendritic cells and macrophages) are additional subsets of white blood cells that are critical to the development of specific immune responses. Our APC Targeting Technology™ uses human monoclonal antibodies to deliver a disease target or antigen directly to APCs. Our mAbs are specific for receptors located on the surface of these APCs which are known to be entry portals for antigen processing pathways. In vivo, the antigen attached to the antibody is specifically delivered to the appropriate processing pathways in APCs, particularly dendritic cells (often referred to as "professional" antigen presenting cells).
Agree with you about CDX-1307, CDX-1127 and the rest of a deep pipeline that is a thing of beauty. What we need is to get some additional supportive data on CDX-1307. The most recent supportive data on CDX-1127 was very good supportive data and it seems to have been overlooked by investors. These deep pipeline products are moving forward and should be nice catalysts going forward.